• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MO

    Altria Group Inc.

    Subscribe to $MO
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

    IPO Year:

    Exchange: NYSE

    Website: altria.com

    Peers

    $PM

    Recent Analyst Ratings for Altria Group Inc.

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    See more ratings

    Altria Group Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. SEC Filings

    View All

    SEC Form 8-K filed by Altria Group Inc.

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    8/6/25 4:57:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Altria Group Inc.

    FWP - ALTRIA GROUP, INC. (0000764180) (Subject)

    8/4/25 4:58:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/30/25 7:22:57 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/30/25 7:03:56 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/23/25 4:50:14 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 11-K filed by Altria Group Inc.

    11-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    6/6/25 11:43:12 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 11-K filed by Altria Group Inc.

    11-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    6/6/25 11:42:47 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 10-K/A filed by Altria Group Inc.

    10-K/A - ALTRIA GROUP, INC. (0000764180) (Filer)

    6/4/25 2:24:55 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    6/3/25 1:16:11 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SD filed by Altria Group Inc.

    SD - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/29/25 2:15:59 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Patterson Katie F claimed ownership of 17,191 shares (SEC Form 3)

    3 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/1/25 2:37:57 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:06:43 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:05:17 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Stoddart Richard S was granted 3,219 shares (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:03:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Shanks Virginia E was granted 3,219 shares, increasing direct ownership by 8% to 43,359 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:02:03 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Munoz George was granted 3,219 shares, increasing direct ownership by 3% to 120,721 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:00:30 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Mcquade Kathryn B. was granted 5,828 shares, increasing direct ownership by 6% to 100,489 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 2:58:53 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Kelly Ennis Debra J was granted 3,219 shares, increasing direct ownership by 5% to 72,297 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 2:57:16 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Robert Matthews was granted 3,219 shares, increasing direct ownership by 26% to 15,492 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 2:55:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Connelly Marjorie Mary was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 2:53:10 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Morgan Stanley initiated coverage on Altria with a new price target

    Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

    1/16/25 7:47:52 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by BofA Securities with a new price target

    BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

    12/6/24 7:56:47 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Citigroup reiterated coverage on Altria with a new price target

    Citigroup reiterated coverage of Altria with a rating of Neutral and set a new price target of $48.00 from $44.50 previously

    10/8/24 10:19:28 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS resumed coverage on Altria

    UBS resumed coverage of Altria with a rating of Sell

    1/23/24 8:04:03 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Stifel resumed coverage on Altria with a new price target

    Stifel resumed coverage of Altria with a rating of Buy and set a new price target of $52.00

    4/14/23 7:44:36 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by UBS with a new price target

    UBS downgraded Altria from Neutral to Sell and set a new price target of $38.00

    11/10/22 6:45:58 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Barclays with a new price target

    Barclays downgraded Altria from Equal Weight to Underweight and set a new price target of $36.00 from $53.00 previously

    6/29/22 7:44:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 Second-Quarter and First-Half Results

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 second-quarter and first-half business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 second-quarter and first-half business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is neces

    7/16/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 Annual Meeting of Shareholders

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

    5/1/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

    4/29/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 First-Quarter Results

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Tuesday, April 29, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 first-quarter business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 first-quarter business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.

    4/15/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    2/27/25 3:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Presents as Part of the Consumer Analyst Group of New York Conference; Reaffirms 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (Altria) (NYSE:MO) is participating in the Consumer Analyst Group of New York Conference in Orlando, Florida today. Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Executive Vice President and Chief Financial Officer, will highlight our exciting progress toward our Vision, discuss how our traditional tobacco businesses continue to support our strategies and provide more detail on our long-term growth aspirations. "We believe our actions over time have positioned Altria to win in U.S. nicotine over the long term," said Billy Gifford. "We have a demonstrated commitment to responsibility, an extensive understanding of U.S. nicotine consumers and a

    2/19/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast From the Consumer Analyst Group of New York Conference

    Altria Group, Inc. (Altria) (NYSE:MO) will host a webcast of its business presentation at the annual Consumer Analyst Group of New York conference in Orlando, Florida, on Wednesday, February 19, 2025, at approximately 10:00 a.m. Eastern Time. The webcast will feature a presentation by Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Executive Vice President and Chief Financial Officer. The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.altria.com/webcasts. An archived copy of the webcast will be available on altria.com. View source version on businesswire.com: https://www.businesswire.com/news/home/2025

    2/5/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Solaris Energy Infrastructure Announces the Addition of Max Yzaguirre to its Board of Directors

    Solaris Energy Infrastructure, Inc. (NYSE:SEI) ("Solaris" or the "Company") announced today that Mr. Max Yzaguirre has been named as an independent member of the Company's Board of Directors (the "Board"), effective January 30, 2025. With the addition of Mr. Yzaguirre, the Board is now composed of 10 members. "We are pleased to welcome Max to our Board and look forward to the value he will bring Solaris," said Bill Zartler, Solaris Chairman and Chief Executive Officer. "His experience developing energy and power related projects as well as his former roles as Chairman of the Texas Public Utility Commission and an ERCOT Board Member will provide unique insight to Solaris as we continue to

    1/30/25 6:39:00 PM ET
    $ARIS
    $MO
    $SEI
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/11/22 2:48:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed

    SC 13G - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/16/21 12:24:24 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/10/21 10:30:29 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care

    Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

    -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

    1/23/24 9:00:00 AM ET
    $ARIS
    $LBC
    $MO
    Oilfield Services/Equipment
    Energy
    Major Banks
    Finance

    Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

    Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

    10/25/23 4:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

    NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. "I could not be more pleased to welcome Drs. Strahlman and Palanki to our Board and look forward to their immediate contributions," stated Dr. Sean Ianchulev, chief executive officer and chief medical officer of Eyenovia. "Each brings decades of medical technology, cl

    7/7/22 8:00:00 AM ET
    $BDX
    $EYEN
    $MO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medicinal Chemicals and Botanical Products

    Altria Participates in the Morgan Stanley Global Consumer and Retail Conference; Reaffirms 2020 Full-Year Earnings Guidance

    RICHMOND, Va.--(BUSINESS WIRE)--Altria Group, Inc. (Altria) (NYSE: MO) is participating today in the Morgan Stanley Global Consumer and Retail Conference. Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Chief Financial Officer, will host virtual meetings with investors to discuss Altria's business fundamentals. 2020 Full-Year Guidance Altria reaffirms its guidance for 2020 full-year adjusted diluted earnings per share (EPS) to be in a range of $4.30 to $4.38. This range represents a growth rate of 2% to 4% from an adjusted diluted EPS base of $4.21 in 2019, as shown in Schedule 1, and excludes the special items recorded in the first nine months of 2020, also sh

    12/2/20 7:00:00 AM ET
    $BUD
    $MS
    $MO
    Beverages (Production/Distribution)
    Consumer Staples
    Investment Bankers/Brokers/Service
    Finance

    Altria Group Inc. Financials

    Live finance-specific insights

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

    4/29/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    2/27/25 3:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2024 Fourth-Quarter and Full-Year Results; Provides 2025 Full-Year Earnings Guidance; Announces New $1 Billion Share Repurchase Program

    Altria Group, Inc. (NYSE:MO) today reports our 2024 fourth-quarter and full-year business results and provides our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "2024 was another pivotal year for Altria, headlined by meaningful progress toward our Vision, strong financial results and significant cash returns to shareholders," said Billy Gifford, Altria's Chief Executive Officer. "Our companies' leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future." "We expect to deliver 2025 full-year adjusted diluted EPS in a range of $5.22 to $5.37. This range re

    1/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on January 10, 2025 to shareholders of record as of December 26, 2024. The ex-dividend date is December 26, 2024. View source version on businesswire.com: https://www.businesswire.com/news/home/20241210514136/en/

    12/11/24 1:45:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2024 Third-Quarter and Nine-Months Results; Reaffirms 2024 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2024 third-quarter and nine-months business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria delivered outstanding results in the third quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid operating companies income growth behind the resilience of Marlboro, and in the oral tobacco products segment, our MST brands continued to drive profitability while on! maintained momentum in the marketplace. We also continued to reward shareholders through a growing dividend and share repurchases while making investments in pursuit of our Visio

    10/31/24 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Increases Quarterly Dividend by 4.1% to $1.02 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors voted to increase our regular quarterly dividend by 4.1% to $1.02 per share versus the previous rate of $0.98 per share. The quarterly dividend is payable on October 10, 2024 to shareholders of record as of September 16, 2024. The ex-dividend date is September 16, 2024. The new annualized dividend rate is $4.08 per share, representing a dividend yield of 7.9% based on our closing stock price of $51.81 on August 21, 2024. Today's dividend increase is consistent with our progressive dividend goal that targets mid-single digits dividend per share growth annually through 2028. This increase marks the 59th dividend incr

    8/22/24 1:15:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2024 Second-Quarter and First-Half Results; Narrows 2024 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2024 second-quarter and first-half business results and narrows our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria's momentum continues to build as we pursue our Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Billy Gifford, Altria's Chief Executive Officer. "In the second quarter, our companies' innovative smoke-free products delivered strong share and volume performance, and we hit meaningful milestones that we believe set us up for future success. NJOY received the first and only marketing granted orders from the FDA for menthol e-vapor products, and we submitted PMTA

    7/31/24 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2024 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $0.98 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2024 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, provided brief remarks and addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 10 nominees for our Board of Directors (Board) named in our 2024 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2

    5/16/24 2:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care